Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company dedicated to the identification, development, and commercialization of therapies for rare diseases, particularly in the fields of nephrology, hepatology, and metabolism. The company markets several products, including Chenodal for the treatment of gallbladder stones, Cholbam for bile acid synthesis disorders, and Thiola for cystinuria. Its key pipeline candidate, Sparsentan, is in Phase III clinical trials for focal segmental glomerulosclerosis and immunoglobulin A nephropathy, both serious kidney conditions. Additionally, Travere sponsors no-cost genetic testing to aid in the diagnosis of cholestasis in children and collaborates with patient advocacy organizations to support the needs of patients and their families. Founded in 2011 and headquartered in San Diego, California, Travere Therapeutics was previously known as Retrophin, Inc., adopting its current name in November 2020.
Top Regions
Top Stages
3 past transactions
Orphan Technologies
Acquisition in 2020
Orphan Technologies Ltd. is a clinical-stage biopharmaceutical company based in Rapperswil, Switzerland, focused on developing innovative therapies for patients with rare disorders, particularly classical homocystinuria (HCU). Incorporated in 2016, the company aims to alleviate the challenges faced by individuals suffering from HCU, a genetic condition that leads to serious cardiovascular, skeletal, neurologic, and ophthalmologic complications. Its lead drug candidate, OT-58, is an optimized enzyme replacement therapy designed to effectively lower homocysteine levels through a targeted mechanism. This therapy not only addresses the symptoms of classical homocystinuria but also holds potential for therapeutic applications in other related diseases. Orphan Technologies operates as a subsidiary of Travere Therapeutics, Inc.
Manchester Pharmaceuticals
Acquisition in 2014
Manchester Pharmaceuticals is a specialty pharmaceutical company dedicated to the identification, development, FDA approval, and commercialization of innovative therapeutic modalities aimed at addressing the unique needs of patients with ultra-rare diseases. By focusing on rare diseases, the company seeks to provide effective treatment options for conditions that often lack adequate therapies, thereby improving patient outcomes in this underserved segment of healthcare.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.